Your browser doesn't support javascript.
loading
Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
Watson, Martin M; Lea, Dordi; Gudlaugsson, Einar; Skaland, Ivar; Hagland, Hanne R; Søreide, Kjetil.
Afiliación
  • Watson MM; Gastrointestinal Translational Research Unit, Stavanger University Hospital, Stavanger, Norway.
  • Lea D; Department of Clinical Medicine, University of Bergen, Bergen, Norway.
  • Gudlaugsson E; Gastrointestinal Translational Research Unit, Stavanger University Hospital, Stavanger, Norway.
  • Skaland I; Department of Clinical Medicine, University of Bergen, Bergen, Norway.
  • Hagland HR; Department of Pathology, Stavanger University Hospital, Stavanger, Norway.
  • Søreide K; Department of Pathology, Stavanger University Hospital, Stavanger, Norway.
Cancer Immunol Immunother ; 69(8): 1627-1637, 2020 Aug.
Article en En | MEDLINE | ID: mdl-32314040
INTRODUCTION: Microsatellite instability (MSI) predict response to anti-PD1 immunotherapy in colorectal cancer (CRC). CRCs with MSI have higher infiltration of immune cells related to a better survival. Elevated Microsatellite Alterations at Tetranucleotides (EMAST) is a form of MSI but its association with PD-L1 expression and immune-cell infiltration is not known. METHODS: A consecutive, observational cohort of patients undergoing surgery for CRC. EMAST and clinicopathological characteristics were investigated against PD-L1, as well as CD3 and CD8 expression in the invasive margin or tumour centre (Immunoscore). Difference in survival between groups was assessed by log rank test. RESULTS: A total of 149 stage I-III CRCs patients, with a median follow up of 60.1 months. Patients with PD-L1+ tumours (7%) were older (median 79 vs 71 years, p = 0.045) and had EMAST+ cancers (OR 10.7, 95% CI 2.2-51.4, p = 0.001). Recurrence-free survival was longer in cancers with PD-L1+ immune cells (HR 0.35, 95% CI 0.16-0.76, p = 0.008, independent of EMAST) and high Immunoscore (HR 0.10, 95% CI 0.01-0.72, p = 0.022). Patients expressing PD-L1 in immune cells had longer disease-specific survival (HR 0.28, 95% CI 0.10-0.77, p = 0.014). CONCLUSIONS: Higher Immunoscore (CD3/CD8 cells) and expression of tumour PD-L1 is found in CRCs with EMAST. Lymphocytic infiltrate and peritumoral PD-L1 expression have prognostic value in CRC.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Neoplasias Colorrectales / Biomarcadores de Tumor / Inestabilidad de Microsatélites / Antígeno B7-H1 / Recurrencia Local de Neoplasia Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2020 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Neoplasias Colorrectales / Biomarcadores de Tumor / Inestabilidad de Microsatélites / Antígeno B7-H1 / Recurrencia Local de Neoplasia Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2020 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Alemania